ArticleFrontiers in cellular and infection microbiology2025
Prevalence of on time administration of carbapenem and its impact on PK/PD target attainment in hospitalized patients: a multicenter retrospective study.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Population pharmacokinetics of imipenem in different populations for individualized dosing: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Toward Model-Informed Precision Dosing of Imipenem: Multicenter External Validation of Population Pharmacokinetic Models in Adult Critically Ill Patients.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: On time administration of carbapenem is important, but there are few data concerning the prevalence of timeliness and its impact on pharmacokinetic/pharmacodynamic (PK/PD) target achievement in hospitalized patients. Methods: This was a multicenter retrospective study. Inpatients who received imipenem or meropenem for more than 3 consecutive days were included according to preset criteria. Patient information and dosing information were collected. The actual administration intervals were compared to the scheduled intervals, and those within a 1-hour error interval were defined as standard time window administration (STWA); otherwise, they were defined as noncompliant time window administration (NTWA). The 100% Results: A total of 474 patients and 1,372 actual administration intervals were included in this study. Among these patients, 82 had drug concentration data and were analyzed for PK/PD target attainment. A total of 427 dosing intervals (31.12%) complied with the standard time window and were STWA, whereas 945 (68.88%) were NTWA. Weekend, night shift, and scheduled dosing intervals were found to be independent influencing factors for STWA. STWA was an independent influencing factor for the 100% Conclusion: Our results indicate a low rate of on time carbapenem administration. The on time carbapenem administration was a risk factor for PK/PD target attainment and should be well controlled in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.